S. Sperl

597 total citations
15 papers, 500 citations indexed

About

S. Sperl is a scholar working on Cancer Research, Hematology and Genetics. According to data from OpenAlex, S. Sperl has authored 15 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cancer Research, 12 papers in Hematology and 7 papers in Genetics. Recurrent topics in S. Sperl's work include Protease and Inhibitor Mechanisms (13 papers), Blood Coagulation and Thrombosis Mechanisms (12 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers). S. Sperl is often cited by papers focused on Protease and Inhibitor Mechanisms (13 papers), Blood Coagulation and Thrombosis Mechanisms (12 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (7 papers). S. Sperl collaborates with scholars based in Germany. S. Sperl's co-authors include Viktor Magdolen, Manfred Schmitt, Jörg Stürzebecher, Olaf G. Wilhelm, Achim Krüger, Nadia Harbeck, Ute Reuning, Bernd Muehlenweg, Horst Kessler and Luis Moroder and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Molecular Biology and European Journal of Biochemistry.

In The Last Decade

S. Sperl

15 papers receiving 470 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Sperl Germany 12 336 185 184 173 94 15 500
MJ Duffy Ireland 5 302 0.9× 83 0.4× 220 1.2× 234 1.4× 103 1.1× 8 503
Katrine E. Pedersen Denmark 8 256 0.8× 171 0.9× 48 0.3× 161 0.9× 48 0.5× 11 369
Rosie Xing Canada 9 226 0.7× 93 0.5× 130 0.7× 322 1.9× 51 0.5× 12 558
Mark Morrow United States 13 151 0.4× 60 0.3× 312 1.7× 392 2.3× 62 0.7× 18 661
Danièle Taras France 8 179 0.5× 61 0.3× 130 0.7× 359 2.1× 33 0.4× 9 558
Gretchen A. Repasky United States 8 95 0.3× 87 0.5× 200 1.1× 403 2.3× 18 0.2× 9 634
Francisca Ugwu Canada 10 208 0.6× 109 0.6× 109 0.6× 266 1.5× 50 0.5× 12 454
J Škrk Slovenia 13 315 0.9× 30 0.2× 190 1.0× 220 1.3× 75 0.8× 33 566
Galit Granot Israel 13 147 0.4× 206 1.1× 83 0.5× 290 1.7× 12 0.1× 28 503
Anne‐Sofie Schrohl Denmark 14 358 1.1× 47 0.3× 382 2.1× 276 1.6× 101 1.1× 21 715

Countries citing papers authored by S. Sperl

Since Specialization
Citations

This map shows the geographic impact of S. Sperl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Sperl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Sperl more than expected).

Fields of papers citing papers by S. Sperl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Sperl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Sperl. The network helps show where S. Sperl may publish in the future.

Co-authorship network of co-authors of S. Sperl

This figure shows the co-authorship network connecting the top 25 collaborators of S. Sperl. A scholar is included among the top collaborators of S. Sperl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Sperl. S. Sperl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

15 of 15 papers shown
1.
Banke, In go J., Matthias Arlt, Markus Mueller, et al.. (2005). Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thrombosis and Haemostasis. 94(11). 1084–1093. 16 indexed citations
2.
Reuning, Ute, S. Sperl, Charlotte Kopitz, et al.. (2003). Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo. Current Pharmaceutical Design. 9(19). 1529–1543. 52 indexed citations
3.
Magdolen, Viktor, Achim Krüger, Sumito Sato, et al.. (2003). Inhibition of the Tumor-Associated Urokinase-Type Plasminogen Activation System: Effects of High-Level Synthesis of Soluble Urokinase Receptor in Ovarian and Breast Cancer Cells in Vitro and in Vivo. Recent results in cancer research. 162. 43–63. 16 indexed citations
4.
Magdolen, Viktor, S. Sperl, Bernd Muehlenweg, et al.. (2002). Natural and Synthetic Inhibitors of The Tumor-Associated Serine Protease Urokinase-Type Plasminogen Activator. Advances in experimental medicine and biology. 477. 331–341. 14 indexed citations
5.
Schroeck, Florian R., et al.. (2002). Interaction of Plasminogen Activator Inhibitor Type-1 (PAI-1) with Vitronectin (Vn): Mapping the Binding Sites on PAI-1 and Vn. Biological Chemistry. 383(7-8). 1143–9. 32 indexed citations
6.
Schroeck, Florian R., Eva‐Kathrin Sinner, Bernd Muehlenweg, et al.. (2002). Interaction of plasminogen activator inhibitor type‐1 (PAI‐1) with vitronectin. European Journal of Biochemistry. 269(1). 184–192. 42 indexed citations
7.
Mueller, Markus, S. Sperl, Jörg Stürzebecher, Wolfram Bode, & Luis Moroder. (2002). (R)-3-Amidinophenylalanine-Derived Inhibitors of Factor Xa with a Novel Active-Site Binding Mode. Biological Chemistry. 383(7-8). 1185–91. 11 indexed citations
8.
Sato, Sumito, Markus Mueller, S. Sperl, et al.. (2002). Natural inhibitors of tumor-associated proteases. 36(2). 131–143. 10 indexed citations
9.
Sperl, S., Jörg Stürzebecher, Achim Krüger, et al.. (2002). The urokinase-type plasminogen activator (uPA) system - A new target for tumor therapy. Max Planck Institute for Plasma Physics. 231–248. 4 indexed citations
10.
Schmitt, Manfred, Viktor Magdolen, S. Sperl, Bernd Muehlenweg, & Nadia Harbeck. (2001). Interference with the urokinase plasminogen activator system: a promising therapy concept for solid tumours. Expert Opinion on Biological Therapy. 1(4). 683–691. 54 indexed citations
11.
Sperl, S., Markus Mueller, Olaf G. Wilhelm, et al.. (2001). The uPA/uPA receptor system as a target for tumor therapy. Drug News & Perspectives. 14(7). 401–401. 21 indexed citations
12.
Sperl, S., Andreas Bergner, Jörg Stürzebecher, et al.. (2000). Urethanyl-3-Amidinophenylalanine Derivatives as Inhibitors of Factor Xa. X-Ray Crystal Structure of a Trypsin/Inhibitor Complex and Modeling Studies. Biological Chemistry. 381(4). 321–329. 6 indexed citations
13.
Żesławska, Ewa, Andrea Schweinitz, Annette Kärcher, et al.. (2000). Crystals of the urokinase type plasminogen activator variant βc-uPA in complex with small molecule inhibitors open the way towards structure-based drug design 1 1Edited by A. Fersht. Journal of Molecular Biology. 301(2). 465–475. 63 indexed citations
14.
Sperl, S., Uwe Jacob, Jörg Stürzebecher, et al.. (2000). (4-Aminomethyl)phenylguanidine derivatives as nonpeptidic highly selective inhibitors of human urokinase. Proceedings of the National Academy of Sciences. 97(10). 5113–5118. 58 indexed citations
15.
Schmitt, Manfred, Olaf G. Wilhelm, Ute Reuning, et al.. (2000). The urokinase plasminogen activator system as a novel target for tumour therapy. Fibrinolysis & proteolysis. 14(2-3). 114–132. 101 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by MJ Duffy Breakdown of academic impact, for papers by Katrine E. Pedersen Breakdown of academic impact, for papers by Rosie Xing Breakdown of academic impact, for papers by Mark Morrow Breakdown of academic impact, for papers by Danièle Taras Breakdown of academic impact, for papers by Gretchen A. Repasky Breakdown of academic impact, for papers by Francisca Ugwu Breakdown of academic impact, for papers by J Škrk Breakdown of academic impact, for papers by Galit Granot Breakdown of academic impact, for papers by Anne‐Sofie Schrohl
Rankless by CCL
2026